Artelo Biosciences Announces Reverse Stock Split
- Aims to maintain Nasdaq listing compliance by meeting minimum share price requirement
- No change in shareholders' proportional ownership
- Automatic adjustment of warrants and derivatives to maintain value
- Indicates company's struggle to maintain minimum share price requirements
- May signal underlying financial or operational challenges
- Could reduce stock liquidity due to fewer outstanding shares
Insights
Artelo's 6-for-1 reverse split aims to maintain Nasdaq listing but signals potential underlying financial challenges.
Artelo Biosciences' announcement of a 6-for-1 reverse stock split is primarily aimed at meeting Nasdaq's continued listing requirement of a $1.00 minimum bid price. This strongly suggests the company's shares have been trading below this threshold, triggering compliance concerns.
The mechanics are straightforward: for every six shares investors currently own, they'll receive one share post-split. While this mathematically increases the share price by a factor of six, it's important to understand that shareholders' proportional ownership remains unchanged and the company's market capitalization stays the same immediately after the split.
Post-split, Artelo will have approximately 546,667 shares outstanding, reduced from about 3.28 million shares. This significant reduction in float could potentially impact liquidity, though maintaining Nasdaq listing helps preserve market access and trading options for investors.
Reverse splits are typically viewed as a red flag by the investment community. Unlike forward splits (which often signal growth and success), reverse splits are usually implemented as a defensive measure by companies experiencing prolonged share price deterioration. The need for such a dramatic ratio (6:1) further suggests significant downward pressure on Artelo's stock.
While this action prevents immediate delisting concerns, it doesn't address the underlying factors that caused the share price decline initially. Investors should closely monitor the company's post-split performance and upcoming financial results to evaluate whether Artelo can maintain compliance long-term without addressing these fundamental challenges.
Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025
SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that on May 20, 2025 Artelo’s Board of Directors approved a 6-for-1 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Company’s common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, June 13, 2025. The Board of Directors determined the 6-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to meet the continued listing requirement of the Nasdaq Stock Market (“Nasdaq”) of a minimum of
As a result of the Reverse Split, each six shares of the Company’s issued and outstanding Common Stock will be automatically combined and converted into one issued and outstanding share of Common Stock. Each shareholder’s pro-rata percentage ownership will remain unchanged as a result of the reverse split and no further action is required by shareholders. All of the Company’s current outstanding warrants to purchase shares of Common Stock and other derivatives automatically adjust per their terms to reflect the reverse split. Immediately after the reverse split becomes effective, there will be approximately 546,667 shares of Common Stock issued and outstanding. For further details, all shareholders are invited to review the 8-K regarding this reverse split which will be filed June 13, 2025.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
What is the ratio of Artelo Biosciences (ARTL) reverse stock split in 2025?
When will ARTL's reverse stock split take effect?
Why is Artelo Biosciences (ARTL) conducting a reverse stock split?
How many shares will ARTL have outstanding after the reverse split?
Will ARTL shareholders need to take any action for the reverse split?
